Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Sep 3;18(3):307-9.
doi: 10.1016/j.cmet.2013.08.014.

FGF21 mimetic shows therapeutic promise

Marc L Reitman  1
Affiliations
Comment

FGF21 mimetic shows therapeutic promise

Marc L Reitman. Cell Metab. .

Abstract

FGF21 is a protein with multiple metabolic actions, currently a bright star beckoning on the metabolic disease therapeutic horizon. Gaich et al. (2013) present the first clinical efficacy trial for an FGF21 mimetic, finding robust lipid-lowering effects, some reduction in body weight, but surprisingly modest effects on glucose homeostasis.

PubMed Disclaimer

Comment on

References

    1. Adams AC, Coskun T, Cheng CC, O'Farrell LS, DuBois SL, Kharitonenkov A. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Molec Metab. 2013 http://dx.doi.org/10.1016/j.molmet.2013.05.005. - DOI - PMC - PubMed
    1. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell. 2012;148:556–567. - PMC - PubMed
    1. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. Effects of a fibroblast growth factor 21 analog, LY2405319, in obese human subjects with type 2 diabetes. Cell Metabolism. 2013 this issue. - PubMed
    1. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, Bauer SM, Wade M, Singhal E, Cheng CC, Volk K, Kuo MS, Gordillo R, Kharitonenkov A, Scherer PE. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17:790–797. - PMC - PubMed
    1. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE. Rational design of a fibroblast growth factor 21-based clinical candidate. PLoS One. 2013;8:e58575. LY2405319. - PMC - PubMed

Publication types